These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 12490770

  • 1. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
    Pini S, Amador XF, Dell'Osso L, Baldini Rossi N, Cassano P, Savino M, Cassano GB.
    Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.
    CNS Drugs; 2002 Jan; 16(6):425-34. PubMed ID: 12027788
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A.
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [Abstract] [Full Text] [Related]

  • 6. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 7. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial.
    Misri S, Reebye P, Corral M, Milis L.
    J Clin Psychiatry; 2004 Sep; 65(9):1236-41. PubMed ID: 15367052
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH, Salinas E.
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [Abstract] [Full Text] [Related]

  • 9. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [Abstract] [Full Text] [Related]

  • 10. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA, Schweizer E, Rickels K.
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [Abstract] [Full Text] [Related]

  • 12. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL, Settle EC, Batey SR, Houser TL, Donahue RM, Ascher JA.
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [Abstract] [Full Text] [Related]

  • 13. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [Abstract] [Full Text] [Related]

  • 14. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
    Bourin M.
    Hum Psychopharmacol; 2003 Apr; 18(3):185-90. PubMed ID: 12672169
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE, Yoon SJ, Kim J, Jung JY, Jeong HS, Cho HB, Shin E, Lyoo IK, Kim TS.
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [Abstract] [Full Text] [Related]

  • 16. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
    Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH.
    J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
    [Abstract] [Full Text] [Related]

  • 17. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.
    Roy-Byrne PP, Perera P, Pitts CD, Christi JA.
    J Clin Psychiatry; 2005 Oct; 66(10):1228-33. PubMed ID: 16259535
    [Abstract] [Full Text] [Related]

  • 18. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
    Rosenthal M.
    J Clin Psychiatry; 2003 Oct; 64(10):1245-9. PubMed ID: 14658975
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
    Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD.
    J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM, Gao KR, Yu H, Shen YF, Li HF.
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.